trending Market Intelligence /marketintelligence/en/news-insights/trending/ttM2jWNztGaxUQrccJk66A2 content esgSubNav
In This List

Medicure files abbreviated application with US FDA for cardiovascular drug

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Medicure files abbreviated application with US FDA for cardiovascular drug

Medicure Inc. filed an abbreviated new drug application to the U.S. FDA for a cardiovascular generic drug, developed as a collaboration between Medicure unit Medicure International Inc. and Apicore US LLC.

The filing was the result of a project focused on the development of an intravenous drug product for an acute cardiovascular indication.

The company and Apicore have entered into an exclusive product supply and development agreement under which Medicure holds all commercial rights.

Medicure currently owns majority interest in Apicore, with an option to acquire the remaining issued shares of Apicore until July 2017.